- All
- Anesthesiology
- Anti-infectives and immunology
- Biologicals
- Blood disorders
- Cardiovascular
- CNS
- Diabetes
- Endocrinology/Sexual health
- Gastrointestinal Diseases
- General modelling
- Lung Diseases
- Methods
- Oncology
- Paediatrics
- Pain
- Peripheral Nervous System
- Safety pharmacology
Goulooze S.C., Yang S, Mesic E, Beerahee M, Post T.M, Mahar K.M.
Population pharmacokinetics of Jesduvroq (daprodustat) in chronic kidney disease patients with anemia. PAGE 2023 [Link to publication]
Goulooze S.C., Noort van M., Berg van den P., Yang S., Beerahee M., Mahar K.M., Post T.M.
Innovative adaptive dose simulations in NONMEM to allow simulation-based model evaluation of titration based dosing, applied to a population dose hemoglobin model for Jesduvroq (daprodustat). PAGE 2023 [Link to publication]
Noort van M., DeJongh J.
Two New User-Friendly Approaches to Assess Pharmacometric Model Identifiability. PAGE 2023 [Link to publication]
Bosch R., Snelder N.
Linking 4GI Glucose Homeostasis and Hall Body Composition Models to study GLP-1R agonist effects on glucose and body weight. PAGE 2023 [Link to publication]
Marostica E., Ahsman M., Van Bragt T., Noukens J., T’joen C., Ulrichts P., Vis P., Rossenu S., Steeg van T. Population PK/PD analysis for efgartigimod Phase 3 study in myasthenia gravis patients. PAGE 2023 [Link to publication]
Struemper H., Rathi C., Muliaditan M., Goulooze S.C., Mantero A., Post T.M., Visser S.A.G. Development of a joint tumor size (TS)−overall survival (OS) modeling and simulation (M&S) framework supporting oncology development decision making. PAGE 2023 [Link to publication]
Goulooze S.C., Muliaditan M., Mantero A., Visser S.A.G., Post T.M., Rathi C., Struemper H. Conditional Overall Survival (OS) Simulations With a Joint Tumor Size (TS)-OS Model to Support Oncology Development Decision Making. PAGE 2023. [Link to publication]
Noort van M., Berg van den P., Post T.M., Beerahee M., Mahar K.M., Yang S. Population dose-Hgb modelling of Jesduvroq (daprodustat) across five phase 3 studies in chronic kidney disease patients with anemia. PAGE 2023 [Link to publication]
Fu Y., Guo T., Taghvafard H., Said M.M., Demeester C., Dudal V., Graaf van der P.H., Snelder N., Hasselt van C.J.G. A translational cardiovascular systems model to quantify drug effects on contractility and other hemodynamic variables. PAGE 2022 [Link to publication]
Berg van der P., Ruppert M., Mesic E., Snelder N., Seelmann A., Heinig R., Joseph A., Garmann D., Lippert J., Eissing T. Finerenone Dose-Exposure-Response for the Primary Kidney Outcome in FIDELIO-DKD Phase III: Population Pharmacokinetic and Time-to-Event Analysis. PAGE 2022. [Link to publication]
Bosch R., Snelder N. Linking the 4GI glucose homeostasis and Hall body composition models to quantify weight loss effects of GLP-1R agonists, and body weight effects on insulin sensitivity. ACoP 2022. [Link to publication]
Mahar K.M., Goulooze S.C., Yang S., Mesic E., Beerahee M., Post T.M.
Population pharmacokinetics of daprodustat across five phase 2b/3 studies in chronic kidney disease (CKD) patients with anemia. ACoP 2022. [Link to publication]
Noort van N., Berg van den P., Post T.M., Beerahee M., Mahar K.M., Yang S.
Population Dose-Hgb modelling of daprodustat across five Phase 3 studies in chronic kidney disease (CKD) patients with anemia. ACoP 2022. [Link to publication]
Goulooze S.C., Noort van N., Berg van den P., Yang S., Beerahee M., Mahar K.M., Post T.M. Innovative adaptive dose simulations in NONMEM to allow simulation-based model evaluation of titration-based dosing, applied to a population doe-hemoglobin model for daprodustat. ACoP 2022. Link to publication
Bosch R. Successful prediction of continuous glucose dynamics and HbA1c response to the GLP-1 and glucagon co-agonist cotadutide using the 4GI- HbA1c systems model The G lucose- G LP-1- G lucagon- G IP- I nsulin ( 4GI ) model. ASCPT 2021. (poster and lecture)